HK152796A - Cyclosporins and their use as pharmaceuticals - Google Patents

Cyclosporins and their use as pharmaceuticals

Info

Publication number
HK152796A
HK152796A HK152796A HK152796A HK152796A HK 152796 A HK152796 A HK 152796A HK 152796 A HK152796 A HK 152796A HK 152796 A HK152796 A HK 152796A HK 152796 A HK152796 A HK 152796A
Authority
HK
Hong Kong
Prior art keywords
residue
mebmt
cyclosporins
dihydro
substituted
Prior art date
Application number
HK152796A
Other languages
English (en)
Inventor
Pietro Bollinger
Johann Jakob Boelsteril
Jean-Francois Borel
Manfred Krieger
Trevor Glyn Payne
Rene P Traber
Roland Wenger
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878714093A external-priority patent/GB8714093D0/en
Priority claimed from GB878714100A external-priority patent/GB8714100D0/en
Priority claimed from GB878714119A external-priority patent/GB8714119D0/en
Priority claimed from GB878714125A external-priority patent/GB8714125D0/en
Priority claimed from GB878714118A external-priority patent/GB8714118D0/en
Priority claimed from GB878714090A external-priority patent/GB8714090D0/en
Priority claimed from GB878714115A external-priority patent/GB8714115D0/en
Priority claimed from GB878714098A external-priority patent/GB8714098D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of HK152796A publication Critical patent/HK152796A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
HK152796A 1987-06-17 1996-08-08 Cyclosporins and their use as pharmaceuticals HK152796A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB878714093A GB8714093D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714100A GB8714100D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714119A GB8714119D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714125A GB8714125D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714118A GB8714118D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714090A GB8714090D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714115A GB8714115D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714098A GB8714098D0 (en) 1987-06-17 1987-06-17 Organic compounds

Publications (1)

Publication Number Publication Date
HK152796A true HK152796A (en) 1996-08-16

Family

ID=27571252

Family Applications (1)

Application Number Title Priority Date Filing Date
HK152796A HK152796A (en) 1987-06-17 1996-08-08 Cyclosporins and their use as pharmaceuticals

Country Status (21)

Country Link
US (1) US5525590A (fr)
EP (1) EP0296122B1 (fr)
JP (2) JPH0832724B2 (fr)
KR (1) KR970010927B1 (fr)
AT (1) ATE95193T1 (fr)
AU (1) AU614086B2 (fr)
CA (1) CA1338728C (fr)
CY (1) CY1939A (fr)
CZ (1) CZ411791A3 (fr)
DE (1) DE3884470T2 (fr)
DK (1) DK173873B1 (fr)
ES (1) ES2059558T3 (fr)
HK (1) HK152796A (fr)
HU (1) HU211678A9 (fr)
IE (1) IE62482B1 (fr)
IL (1) IL86751A (fr)
MY (1) MY103582A (fr)
NZ (1) NZ225041A (fr)
PT (1) PT87745B (fr)
SA (1) SA97170746A (fr)
SK (1) SK411791A3 (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283801A3 (fr) * 1987-03-27 1990-05-30 Abbott Laboratories Essais de polarisation par fluorescence pour cyclosporine A et les métabolites et immunogènes et anticorps apparentés
US5236899A (en) * 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
BE1003009A5 (fr) * 1989-02-09 1991-10-22 Sandoz Sa Nouvelles compositions pharmaceutiques a base de cyclosporines.
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
GB8916901D0 (en) * 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
US5122511A (en) * 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
ATE147619T1 (de) * 1992-05-13 1997-02-15 Sandoz Ag Opthalmische zusammensetzungen enthaltend ein cyclosporin
SK278290B6 (en) * 1992-09-07 1996-08-07 Milan Stuchlik Medicaments with n-methylated cyclic undecapeptides
PT589843E (pt) 1992-09-25 2002-04-29 Novartis Ag Composicoes farmaceuticas contendo ciclosporinas
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
US6187547B1 (en) 1993-09-08 2001-02-13 Novartis Ag Assay kit
GB9318612D0 (en) * 1993-09-08 1993-10-27 Sandoz Ltd An assay
KR20040068613A (ko) * 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR970704464A (ko) 1994-11-03 1997-09-06 가이슐러 에리히, 데커 카를-루드빅 간단한 조성 및 높은 생물 유효성을 갖는 경구 투여용의 신규 사이클로스포린 제형 및 이의 제조방법(Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them)
GR1002687B (el) * 1995-04-17 1997-05-06 Novartis Ag (Novartis Sa) (Novartis Inc.) Διαδικασια παραγωγης.
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE19549852B4 (de) 1995-11-29 2009-06-04 Novartis Ag Cyclosporin enthaltende Präparate
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
DE19882037T1 (de) * 1997-01-30 1999-12-16 Novartis Ag Hartgelatinekapsel, die im wesentlichen ölfreie pharmazeutische Zusammensetzungen enthält
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
KR100585348B1 (ko) * 1997-10-08 2006-06-01 이소테크니카 인코포레이티드 중수소화된 시클로스포린 유사체 및 면역조절제로서 그의용도
AU748334B2 (en) 1997-10-16 2002-05-30 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with NF-AT3 function
JP4350898B2 (ja) 1998-07-01 2009-10-21 デビオファーム・ソシエテ・アノニム 活性の特徴が改善された新規のシクロスポリン
NZ512599A (en) 1998-12-30 2003-10-31 Dexcel Ltd Formulation for cyclosporin administration featuring a hydrophilic solvent and a surfactant with a HLB of less than 5
US6255280B1 (en) * 1999-04-08 2001-07-03 University Of Kentucky Research Foundation Protection against traumatic brain injury
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6784156B2 (en) 2001-03-05 2004-08-31 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of respiratory diseases
GB0113663D0 (en) * 2001-06-05 2001-07-25 Novartis Ag Use of organic compounds
US20030087813A1 (en) 2001-10-12 2003-05-08 Or Yat Sun Cyclosporin analogs for the treatment of lung diseases
US6809077B2 (en) 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
AU2007221839B2 (en) * 2001-10-19 2011-05-12 Aurinia Pharmaceuticals Inc. Synthesis of cyclosporin analogs
ATE332917T1 (de) 2001-10-19 2006-08-15 Isotechnika Inc Synthese von cyclosporin-analogen
AU2002331510B2 (en) * 2001-10-19 2008-05-01 Aurinia Pharmaceuticals Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
EP2116228A1 (fr) 2001-10-19 2009-11-11 Isotechnika Inc. Nouveaux préconcentrés de microémulsion analogue de cyclosporine
US7012065B2 (en) 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
AU2004222306A1 (en) * 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
TW200505946A (en) * 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
KR20060134198A (ko) * 2004-04-08 2006-12-27 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. Ｊｎｋ 저해제 및 시클로스포린을 포함하는 조성물
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US7511013B2 (en) * 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US7378391B2 (en) * 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US7361636B2 (en) * 2004-10-06 2008-04-22 Amr Technology, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
EP1828229A4 (fr) * 2004-12-17 2010-06-30 Isotechnika Inc Metabolites d'analogues de la cyclosporine
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
WO2008036244A1 (fr) * 2006-09-18 2008-03-27 The Burham Institute For Medical Research Utilisation de cyclosporine a pour sensibiliser des cellules cancéreuses résistantes à des ligands de récepteur de mort
WO2008084368A2 (fr) * 2007-01-04 2008-07-17 Debiopharm Sa Cyclosporine non immunosuppressive pour le traitement de la dystrophie musculaire congénitale d'ullrich
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
JP5726733B2 (ja) * 2008-07-30 2015-06-03 シクロフィリン ファーマシューティカルズ コープ． 非免疫抑制性シクロスポリン類似体分子
CN102245625A (zh) 2008-10-17 2011-11-16 威斯康星旧生研究基金会 制备有生物活性的α-β肽的方法
AU2009334790B2 (en) * 2008-12-31 2016-09-08 Scynexis, Inc. Derivatives of cyclosporin A
AU2010208071C1 (en) * 2009-01-30 2013-06-20 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US8481483B2 (en) * 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) * 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8367053B2 (en) * 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) * 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
DE102009037551A1 (de) * 2009-08-17 2011-02-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Cyclosporinderivate
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2011141891A1 (fr) 2010-05-12 2011-11-17 Debio Recherche Pharmaceutique S.A. Utilisation de composés cycloundécadepsipeptides
BR112013014890B1 (pt) 2010-12-15 2023-10-24 Contravir Pharmaceuticals, Inc Composto análogo de moléculas pertencentes à família ciclosporina, composição farmacêutica compreendendo o mesmo, uso terapêutico ou profilático do referido composto e processos para a preparação dos mesmos
WO2012145427A1 (fr) 2011-04-18 2012-10-26 The Trustees Of Columbia University In The City Of New York Méthodes de traitement du cancer à l'aide de cyclosporine et de dérivés de cyclosporine
JP2015532277A (ja) 2012-09-29 2015-11-09 ノバルティス アーゲー 環状ペプチドおよび医薬としてのその使用
WO2014085623A1 (fr) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Nouveaux analogues de [n-me-4-hydroxyleucine]-9-cyclosporine
US9221878B2 (en) 2013-08-26 2015-12-29 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
MX2016011993A (es) 2014-03-14 2016-12-09 Novartis Ag Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (fr) 2014-10-14 2023-12-13 Novartis AG Molécules d'anticorps de pd-l1 et leurs utilisations
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
EP3233918A1 (fr) 2014-12-19 2017-10-25 Novartis AG Polythérapies
BR112017018908A2 (pt) 2015-03-10 2018-04-17 Aduro Biotech, Inc. composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017019897A1 (fr) 2015-07-29 2017-02-02 Novartis Ag Polythérapies comprenant des molécules d'anticorps contre tim -3
CA2996064C (fr) 2015-08-18 2024-02-13 Novation Pharmaceuticals Inc. Derives de benzopyrane et utilisations associees
BR112018008904A2 (pt) 2015-11-03 2018-11-27 Janssen Biotech Inc anticorpos que se ligam especificamente a tim-3 e seus usos
MX2018007423A (es) 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
EP3507367A4 (fr) 2016-07-05 2020-03-25 Aduro BioTech, Inc. Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
AU2018290237A1 (en) 2017-06-22 2020-01-16 Novartis Ag Antibody molecules to CD73 and uses thereof
EP3642240A1 (fr) 2017-06-22 2020-04-29 Novartis AG Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (fr) 2018-05-31 2019-12-05 Novartis Ag Molécules d'anticorps anti-cd73 et leurs utilisations
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
CN114208781B (zh) * 2022-01-20 2022-12-20 河南农业大学 一种抑制草地贪夜蛾龄期的方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210581A (en) * 1975-11-04 1980-07-01 Sandoz Ltd. Organic compounds
CH614931A5 (fr) * 1975-11-04 1979-12-28 Sandoz Ag
IE54936B1 (en) * 1980-02-14 1990-03-28 Sandoz Ltd A method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
CH667274A5 (de) * 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
GB8407618D0 (en) * 1984-03-23 1984-05-02 Sandoz Ltd Organic compounds
EP0194972B1 (fr) * 1985-03-11 1992-07-29 Sandoz Ag Cyclosporines
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"

Also Published As

Publication number Publication date
DK326588A (da) 1988-12-18
AU614086B2 (en) 1991-08-22
HU211678A9 (en) 1995-12-28
EP0296122B1 (fr) 1993-09-29
JPS6445396A (en) 1989-02-17
KR890000519A (ko) 1989-03-15
JP2772372B2 (ja) 1998-07-02
CY1939A (en) 1997-05-16
PT87745B (pt) 1992-10-30
MY103582A (en) 1993-08-28
SK411791A3 (en) 1995-07-11
NZ225041A (en) 1991-03-26
US5525590A (en) 1996-06-11
IE881807L (en) 1988-12-17
CZ411791A3 (en) 1993-02-17
JPH0832724B2 (ja) 1996-03-29
CA1338728C (fr) 1996-11-19
ATE95193T1 (de) 1993-10-15
IL86751A0 (en) 1988-11-30
ES2059558T3 (es) 1994-11-16
DK326588D0 (da) 1988-06-15
AU1767988A (en) 1988-12-22
JPH0848696A (ja) 1996-02-20
SA97170746A (ar) 2005-12-03
KR970010927B1 (ko) 1997-07-02
PT87745A (pt) 1988-07-01
EP0296122A2 (fr) 1988-12-21
IL86751A (en) 1994-02-27
DE3884470D1 (de) 1993-11-04
EP0296122A3 (en) 1990-06-20
DE3884470T2 (de) 1994-03-10
IE62482B1 (en) 1995-02-08
DK173873B1 (da) 2002-01-21

Similar Documents

Publication Publication Date Title
EP0296122A3 (en) Cyclosporins and their use as pharmaceuticals
ATE72988T1 (de) Fettsaeure-zusammensetzungen.
PL300066A1 (en) Novel 7-(substituted)-8-(substituted)-9-(substituted amino)-6-demethyl-6-deoxy-tyetracyclines, methods of obtaining them and pharmaceutical composition
DE69226537T2 (de) Antivirale 2-ethyl-1h-imidazo(4,5-c)chinolin-4-amine
IL89835A0 (en) Substituted azetidinones,their preparation and pharmaceutical compositions containing them
HUT67691A (en) 7-(substituted)-8-(substituted)-9-[(substituted-glycyl)amido]6-demethyl-6-deoxytetracyclines, pharmaceutical compositions containing them and process to prepare them
ZA886727B (en) Azithromycin and derivatives as antiprotozoal agents
HUT71594A (en) Process to prepare 9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracyclines and pharmaceutical compns. contg. them
MY111201A (en) New imidazopyridines
NZ226845A (en) 2', 3'-dideoxy-2'-fluoronucleosides; pharmaceutical compositions and processes for their preparation
EP0296573A3 (en) Novel nucleosides, their preparation and pharmaceutical novel nucleosides, their preparation and pharmaceutical compositions compositions
GR3006366T3 (fr)
GB9211783D0 (en) Amide derivatives
UA27022C2 (uk) Похідhі карбазолоhу як проміжhі сполуки для отримаhhя оhдаhсетроhу
ES2153842T3 (es) Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central.
ES2059942T3 (es) Imidazo(4,5-c)piridinas heteroaril-sustituidas.
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
DE3854158T2 (de) Nucleosid-analoge.
MY103900A (en) 6-substituted 2'', 3''-dideoxynucleosides and pharmaceutical compositions

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20080613